linjc16/ctgov huggingface dataset:
Energy Expenditure of High Intensity Functional Training

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the energy expenditure and intensity of a High Intensity Functional Training (HIFT) session in overweight and obese adult men and women.

Detailed Description
-----------------
High Intensity Functional Training (HIFT), which alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods, may offer an attractive, time efficient alternative to traditional aerobic exercise. Variations of HIFT such as Cross Fit, home workout videos (ie.P90x and Insanity), and boot-camp style group exercise classes have become increasingly popular. The cardiovascular benefits of HIFT have been demonstrated; however, by doing this study researchers hope to get more information regarding the potential effectiveness of HIFT for weight management, such as the actual level of energy expenditure and exercise intensity elicited by a HIFT session.

Official Title
-----------------
Energy Expenditure of High Intensity Functional Training

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: HIFT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body Mass Index (BMI) between 25.0 and 39.9 Currently participating in HIFT (boot-camp) classes at Kirmayer Fitness Center

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HIFT<br>High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions. | Other: HIFT<br>* Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.<br>* Other names: High Intensity Functional Training;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Energy expenditure measured using indirect calorimetry | Energy expenditure will be measured using indirect calorimetry | Energy expenditure will be obtained across a 2 week period after each of 3 exercise sessions |
Indonesian Registry on Atrial Fibrillation

Study Overview
=================
Brief Summary
-----------------
Our rationale of creation of this registry stems from the fact that the use of VKA in patients with AF is a double-edged sword, physicians face tremendous burden in assigning patients with VKA, due to risk of Bleeding complications despite its potential benefit. We intend to seek a safe and beneficial range of INR on Indonesian patients.

Official Title
-----------------
Indonesian Registry on Atrial Fibrillation

Conditions
-----------------
Atrial Fibrillation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >18 years old Diagnosis of valvular or nonvalvular AF Exclusion Criteria: Reversible AF Patients who have been enrolled as a respondent on other clinical studies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Major Adverse Cardiovascular Events | Major Adverse Cardiovascular Events including stroke/transient ischemic attack, thromboembolism, acute coronary syndrome | 24 months | 
| Number of Participants with Bleeding Events | Intracranial bleeding, gastrointestinal bleeding | 24 months | 
| Mortality Rate | All-cause Mortality | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrial fibrillation, registry, anticoagulant
Evaluation of Respiratory Heast Loss as a Physiologic Patient Monitor for Acute Care Medicine

Study Overview
=================
Brief Summary
-----------------
To evaluate the utility of respiratory heat loss measurements as a physiologic monitor.

Detailed Description
-----------------
Respiratory Heat Loss Measured in Joules Per Minute

Official Title
-----------------
Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine

Conditions
-----------------
Respiratory Heat Loss

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective surgical procedures. Exclusion Criteria: Severe pulmonary disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine | Respired gas heat content | 1 year. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Enthalpy, Physiologic Monitors, Critical Care Medicine
EU/LA Pearl Index Study - Transdermal Contraceptive Patch

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to prove efficacy and safety of a new contraceptive patch.

Official Title
-----------------
Multicenter, Open-label, Uncontrolled Study to Investigate the Efficacy and Safety of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen for 13 Cycles in 1650 Healthy Female Subjects

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: Ethinylestradiol/Gestodene (BAY86-5016)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Requiring contraception Normal cervical smear Smokers not older than 30 years History of regular cyclic menstrual periods Exclusion Criteria: Pregnancy or lactation Obesity (BMI> 30 kg/m2 Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic) Use of other contraceptive methods than study medication

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: Ethinylestradiol/Gestodene (BAY86-5016)<br>* 7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of pregnancy |  | 13 treatment cycles each consisting of 28 days and follow-up period of 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cervical smear |  | 13 treatment cycles each consisting of 28 days | 
| Adverse events |  | 13 treatment cycles each consisting of 28 days | 
| Bleeding pattern and cycle control |  | 13 treatment cycles each consisting of 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fertility control, Contraception
A Post Marketing Surveillance Program for NutropinAq® in Paediatric Growth Disorders

Study Overview
=================
Brief Summary
-----------------
This study is a multicenter, open label, observational, post marketing surveillance study of NutropinAq® in Austria, France, Germany, Italy, Spain, Romania and United Kingdom to collect long-term safety and effectiveness information on NutropinAq® during treatment of paediatric growth disorders.

Detailed Description
-----------------
The objective of this study is to collect long term safety and effectiveness information on Ipsen's growth hormone (GH) NutropinAq® regarding treatment of paediatric growth disorders for which GH is indicated.

Official Title
-----------------
International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program for NutropinAq® [Somatropin (rDNA Origin) Injection]

Conditions
-----------------
Growth Hormone Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children of either sex who are treated with NutropinAq® for the treatment of growth failure Patients who are willing to comply with follow-up appointments throughout study participation Written informed consent signed by both parents or by the liable parent or by the legal guardian when applicable, and by the child when applicable Exclusion Criteria: Patients not treated with NutropinAq® Patients with closed epiphyses Patients with active neoplasia

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with adverse events | Description and incidence of any Serious Adverse Event (SAE) and all related (serious and non-serious) Adverse Events (AEs). | Every 3 months until study completion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment height measurements until epiphyseal closure is achieved. |  | Every 3 months until study completion |
Combined Malonic and Methylmalonic Aciduria (CMAMMA): Gene Identification and Outcome Study

Study Overview
=================
Brief Summary
-----------------
The investigators are interested in learning more about the changes found in the condition called Combined elevation of Malonic and MethylMalonic Acid, or CMAMMA.  Malonic, or MA and MethylMalonic, or MMA, are acids formed from the breakdown of protein under normal conditions. However, in the condition called CMAMMA there is an increase of these acids in the blood and urine, which is not normal. Some people with high MA and MMA in their blood and urine have a serious disease, starting as a baby or young child that includes heart disease and problems in learning. These people have changes in a special enzyme called Malonyl CoA Decarboxylase (MCD). Other people who have a high level of MA and MMA do not have any obvious illness. The investigators are not sure why they have high levels of MA and MMA and why they are not sick. The goal of this study is to learn more about why some people have a high level of MA and MMA and to make sure there are no medical problems as a result of these high levels. The investigators also want to find out which gene and enzyme cause the high levels of MA and MMA.

Conditions
-----------------
Malonic Aciduria, Methylmalonic Acidemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elevated Malonic and Methylmalonic Acid in blood and urine Any age Any sex Asymptomatic Exclusion Criteria: Defect in malonyl-coenzyme A decarboxylase (MCD) enzyme History of metabolic acidosis, developmental delay and seizures
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| non-classical CMAMMA, classical CMAMMA<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
malonic and methylmalonic aciduria, malonyl-coenzyme A decarboxylase, MLYCD
Construction of a Prediction Model for Metachronous Colorectal Adenoma

Study Overview
=================
Brief Summary
-----------------
The study aimed to explore the independent risk factors for the metachronous colorectal adenoma after endoscopic resection, and construct the prediction model of metachronous colorectal adenoma, in order to provide theoretical basis for postoperative follow-up time of patients, and allocate limited medical resources.

Detailed Description
-----------------
A large cohort of eligible patients were included in the analysis, and classified into derivation and validation cohorts at a ratio of 7:3. Demographic and clinicopathological characteristics of participants were utilized to develop a prediction model for metachronous colorectal adenoma. In the derivation cohort, the LASSO regression method was applied to filter variables and multivariate logistic regression analysis was used to identify important predictors.A prediction model was established based on the results of multivariate logistic regression analysis. The predictive performance of the model was evaluated with respect to its discrimination, calibration and clinical usefulness.

Official Title
-----------------
Construction of a Prediction Model for Metachronous Colorectal Adenoma

Conditions
-----------------
Metachronous Colorectal Adenoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged ≥18 and ≤75 years old. Patients with complete data on demography and clinicopathology. Exclusion Criteria: Patients with a history of inflammatory bowel disease, enterophthisis, familial adenomatous polyposis, P-J syndrome and intestinal lymphoma. Patients with a previous history of colorectal neoplasm. Patients with a history of severe systemic diseases. Lack of complete clinical data for analysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with metachronous colorectal adenomas<br> | |
| patients without metachronous colorectal adenomas<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic characteristics of patients with metachronous colorectal adenomas checklist | Age (years), sex (man/woman), family history of colorectal cancer (in first-degree relatives, including parents and siblings), history of smoking (never, past, current), history of alcohol consumption (never, past, current), regular use of non-steroidal anti-inflammatory drugs | 3 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cumulative recurrence rate of metachronous colorectal adenomas | Cumulative recurrence rate | 3 year |
AS-OCT Guided Treatment of Diffuse CSCC

Study Overview
=================
Brief Summary
-----------------
A prospective study was performed on 8 eyes of 8 patients who underwent amniotic membrane graft after diffuse conjunctival squamous cell neoplasia excision followed by topical mitomycin C 0.04% eye drop between March 2014 and January 2018.

Detailed Description
-----------------
Surgical excision of the conjunctival tumour . A superficial corneal scraping was performed for corneal lesion then double freeze-thaw cryotherapy was applied to limbal edge and conjunctival margins.The amniotic membrane graft was secure and attached to the sclera and conjunctiva using ﬁbrin glue.Topical mitomycin C 0.04%eye drop was prescribed 4 times daily per treatment cycle (1 cycle=1 week on 1 week off).

Official Title
-----------------
Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Conjunctival Squamous Cell Carcinoma (CSCC) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)

Conditions
-----------------
Conjunctival Neoplasms

Intervention / Treatment
-----------------
* Procedure: Treatment of diffuse ocular surface squamous neoplasia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diffuse Ocular Surface Squamous Neoplasia Exclusion Criteria: localized OSSN (less than ﬁve clock hours in limbal extent)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The recurrence rate of lesion | Any recurrence which is detected clinically or/and by AS-OCT | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
conjunctiva, squamous neoplasia, amniotic
Efficacy and Tolerance of Hypertonic Sodium Chloride (NaCl 5%) Eye Drops Without Preservatives in Corneal Edema

Study Overview
=================
Brief Summary
-----------------
Corneal edema is frequently found in clinical practice as a common sign of acute corneal disease due to different etiologies that cause an accumulation of extracellular fluid in the cornea. The present unicentric clinical trial aims to evaluate the efficacy and tolerance of an ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in participants suffering from symptomatic corneal edema.

Official Title
-----------------
Unicentric Clinical Trial on the Clinical Efficacy and Tolerance of the Treatment With an Ophthalmic Solution of Hypertonic Sodium Chloride (NaCl 5%) Without Preservatives in Patients Suffering From Symptomatic Corneal Edema

Conditions
-----------------
Corneal Edema

Intervention / Treatment
-----------------
* Device: hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years Clinical diagnosis of symptomatic corneal edema related to chronic epithelial, secondary to corneal dystrophies, controlled infectious and inflammatory pathologies and surgical trauma already resolved. No need for keratoplasty in the 6 months following the start of the study Exclusion Criteria:. Visual acuity less than 1/20 in both eyes Corneal edema caused by the following acute etiologies: trauma, infection, inflammation or Stevens-Johnson syndrome. Glaucoma or uncontrolled hypertension. Known allergy to any of the ingredients of the product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NaCl 5%<br>Hypertonic sodium chloride (NaCl 5%) eye drops solution in single-dose, without preservatives, administered every 8 hours for 28 days. | Device: hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose<br>* Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container<br>* Other names: Ocumax 5 eye drops solution in single-dose;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Change from Baseline in Visual acuity |  | Baseline, Day 7 and Day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Change from Baseline in Corneal Thickness | Micrometers | Baseline, Day 7 and Day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
corneal edema, sodium chloride, single-dose